Clinical Trial Update: Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating SB424323 in combination with aspirin for non-valvular atrial fibrillation at low to intermediate stroke risk has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• Aspirin (Aspirin)
• SB424323 (SB424323)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Fibrillation, Atrial, Atrial Fibrillation | Phase 2 | Status: COMPLETED